| Jean Claude Pilet, MD | |
|
78 W Park Ave, Vineland, NJ 08360-3560 | |
| (856) 696-1848 | |
| Not Available |
| Full Name | Jean Claude Pilet |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 78 W Park Ave, Vineland, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750442125 | NPI | - | NPPES |
| 3758109 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 25MA024696 (New Jersey) | Primary |
| Entity Name | Community Health Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700816816 PECOS PAC ID: 9335040419 Enrollment ID: O20040402000981 |
News Archive
Cervical cancer is a major issue in low- and middle-income countries due to the lack of adequate screening such as routine Pap smear testing.
The world's first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID' providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been obtained using 4DMedical's unique XV Technology.
Roche and IBM announced today an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review in the July/August issue of "CA: A Cancer Journal for Clinicians" reports that two out of three survivors of childhood cancer have at least one chronic or late-occurring health problem following their cancer therapy, with about one in three having serious or life-threatening complications. These effects are often seen decades after therapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jean Claude Pilet, MD 78 W Park Ave, Vineland, NJ 08360-3560 Ph: (856) 691-6366 | Jean Claude Pilet, MD 78 W Park Ave, Vineland, NJ 08360-3560 Ph: (856) 696-1848 |
News Archive
Cervical cancer is a major issue in low- and middle-income countries due to the lack of adequate screening such as routine Pap smear testing.
The world's first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID' providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been obtained using 4DMedical's unique XV Technology.
Roche and IBM announced today an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A review in the July/August issue of "CA: A Cancer Journal for Clinicians" reports that two out of three survivors of childhood cancer have at least one chronic or late-occurring health problem following their cancer therapy, with about one in three having serious or life-threatening complications. These effects are often seen decades after therapy.
› Verified 8 days ago
Dr. Christopher Ryan Bruno, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2835 S Delsea Drive, Vineland, NJ 08360 Phone: 856-696-0020 Fax: 856-205-1721 | |
Saul Bresalier, D.O. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 251 S Lincoln Ave, Vineland, NJ 08361 Phone: 856-691-8188 Fax: 856-691-0421 | |
Barnard A Kaplan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 251 S Lincoln Ave, Vineland, NJ 08361 Phone: 856-691-8188 Fax: 856-691-0421 | |
Ekta Patel, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 251 S Lincoln Ave, Vineland, NJ 08361 Phone: 856-691-8188 Fax: 856-691-0421 | |
Alice Williams, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 251 S Lincoln Ave, Vineland, NJ 08361 Phone: 856-691-8188 | |
Sydney L Tyson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 251 S Lincoln Ave, Vineland, NJ 08361 Phone: 856-691-8188 Fax: 856-691-0421 | |
Catherine L Wisda, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1318 S Main Rd, Bldg. 2a, Vineland, NJ 08360 Phone: 856-692-8008 Fax: 856-692-8044 |